PE20010983A1 - Forma de dosificacion de farmaco en capas impulsada por hidrogel - Google Patents
Forma de dosificacion de farmaco en capas impulsada por hidrogelInfo
- Publication number
- PE20010983A1 PE20010983A1 PE2000001381A PE0013812000A PE20010983A1 PE 20010983 A1 PE20010983 A1 PE 20010983A1 PE 2000001381 A PE2000001381 A PE 2000001381A PE 0013812000 A PE0013812000 A PE 0013812000A PE 20010983 A1 PE20010983 A1 PE 20010983A1
- Authority
- PE
- Peru
- Prior art keywords
- sertraline
- releases
- weight
- formulation
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMA DE DOSIFICACION PARA LIBERACION CONTROLADA DE SERTRALINA QUE COMPRENDE 1)UN NUCLEO QUE CONTIENE a)SERTRALINA AL MENOS 20mgA, EN FORMA DE LACTATO, ACETATO, ASPARTATO; b)POLIMERO ARRASTRADOR; c)AGENTE FLUIDIZANTE; d)AGLUTINANTE; e)POLIMERO INTENSIFICADOR DE LA CONCENTRACION; f)SOLUBILIZADOR; g)UN ANTIOXIDANTE; h)POLIOXIDO DE ETILENO DE PESO MOLECULAR 500 000; CONSTITUYENDO 20%; b)UNA COMPOSICION HINCHABLE EN AGUA SITUADA EN UNA REGION SEPARADA DENTRO DEL NUCLEO; QUE NO CONTIENE AGENTE ACTIVO OSMOTICO; 2)UN REVESTIMIENTO EN TORNO A DICHO NUCLEO QUE ES PERMEABLE E INSOLUBLE AL AGUA; TIENE AL MENOS UNA ABERTURA DE SUMINISTRO A TRAVES DEL MISMO; DESPUES DE LA INTRODUCCION DE LA FORMULACION LIBERA SERTRALINA AL ENTORNO CON UNA VELOCIDAD MEDIA DE 6% A 10% EN PESO DESDE LA SEGUNDA HORA HASTA LA DUODECIMA HORA Y LIBERA MENOS DE 25% EN PESO DURANTE LAS 2 PRIMERA HORAS Y LIBERA AL MENOS EL 70% EN PESO AL CABO DE LA DUODECIMA HORA.LA FORMULACION SE GRANULA EN HUMEDO EMPLEANDO UNA MEZCLA DE ALCOHOL Y AGUA; LA FORMULACION LIBERA SERTRALINA A VELOCIDADES Y CANTIDADES DETERMINADAS CON EL FIN DE REDUCIR LA INCIDENCIA Y GRAVEDAD DE EFECTOS SECUNDARIOS QUE SE ORIGINA POR EL SUMINISTRO EXCESIVO DE SERTRALINA EN EL ESTOMAGO; INTENSIFICAN LA ABSORCION EN EL COLON, AUMENTAN LA CONCENTRACION DE SERTRALINA DISUELTA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17210899P | 1999-12-23 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010983A1 true PE20010983A1 (es) | 2001-10-01 |
Family
ID=22626396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000001381A PE20010983A1 (es) | 1999-12-23 | 2000-12-21 | Forma de dosificacion de farmaco en capas impulsada por hidrogel |
Country Status (15)
Country | Link |
---|---|
US (1) | US6899896B2 (es) |
EP (1) | EP1239839A2 (es) |
JP (1) | JP2003518487A (es) |
AR (1) | AR027066A1 (es) |
AU (1) | AU1724301A (es) |
BR (1) | BR0016707A (es) |
CA (1) | CA2395231C (es) |
CO (1) | CO5271728A1 (es) |
GT (1) | GT200000220A (es) |
MX (1) | MXPA02006335A (es) |
PA (1) | PA8508901A1 (es) |
PE (1) | PE20010983A1 (es) |
TN (1) | TNSN00251A1 (es) |
UY (1) | UY26493A1 (es) |
WO (1) | WO2001047498A2 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
YU35302A (sh) * | 1999-12-23 | 2005-03-15 | Pfizer Products Inc. | Dozirani oblik leka sa inicijalnim hidrogelom |
BR0211028A (pt) * | 2001-06-22 | 2004-06-15 | Pfizer Prod Inc | Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto |
JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
CN1596100A (zh) * | 2001-09-28 | 2005-03-16 | 麦克内尔-Ppc股份有限公司 | 可食用组合物及含可食用外壳的制剂 |
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
KR20120034211A (ko) * | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20040081695A1 (en) * | 2002-09-28 | 2004-04-29 | Sowden Harry S | Dosage forms having an inner core and an outer shell |
EP1558561A1 (en) * | 2002-11-07 | 2005-08-03 | Torrent Pharmaceuticals Ltd | Process for preparation of polymorphic form of sertraline hydrochloride |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
BRPI0413277A (pt) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas |
KR20070009671A (ko) * | 2004-05-06 | 2007-01-18 | 사이덱스 인크 | 세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제 |
WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20060239956A1 (en) * | 2005-04-26 | 2006-10-26 | Lulu Henson | Preparation and use of hydrogels |
WO2007056205A2 (en) * | 2005-11-04 | 2007-05-18 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
WO2007057762A2 (en) * | 2005-11-16 | 2007-05-24 | Pfizer Limited | Osmotic bi-layer tablet |
CN100563637C (zh) * | 2006-10-13 | 2009-12-02 | 北京红林制药有限公司 | 一种控释给药的药芯组合物和控释制剂及其制备方法 |
ECSP077628A (es) * | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
MX367327B (es) * | 2009-12-04 | 2019-08-15 | Sunovion Pharmaceuticals Inc | Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos. |
US10485770B2 (en) | 2009-12-21 | 2019-11-26 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
WO2016020936A2 (en) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | A novel oral gastroretentive pharmaceutical dosage form |
JP6455293B2 (ja) * | 2015-04-21 | 2019-01-23 | ニプロ株式会社 | セルトラリン及び/又はその薬学上許容しうる塩を含む製剤 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
USRE33994E (en) | 1983-08-16 | 1992-07-14 | Burroughs Wellcome Co. | Pharmaceutical delivery system |
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
US4624847A (en) | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4865598A (en) | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
EP0277092B1 (de) | 1987-01-14 | 1992-01-29 | Ciba-Geigy Ag | Therapeutisches System für schwerlösliche Wirkstoffe |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4946687A (en) | 1987-10-02 | 1990-08-07 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US4971998A (en) | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4837111A (en) | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
FI101344B1 (fi) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta |
US5030456A (en) | 1988-11-07 | 1991-07-09 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
DD295760A5 (de) | 1989-01-31 | 1991-11-14 | Martin-Luther-Universitaet Halle Wittenberg,De | Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung |
US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US5019396A (en) | 1989-05-12 | 1991-05-28 | Alza Corporation | Delivery dispenser for treating cardiac arrhythmias |
US5273752A (en) | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
US5035897A (en) | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US5091190A (en) | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5200197A (en) | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5128145A (en) | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
DK0550641T3 (da) | 1990-09-28 | 1994-08-22 | Pfizer | Dispenseringsanordning indeholdende et hydrofobt medium |
US5284662A (en) | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
PT100944B (pt) | 1991-10-10 | 2000-02-29 | Alza Corp | Dispositivo para o fornecimento osmotico de farmacos com paredes de materiais hidrofobicos |
US5183942A (en) | 1991-11-05 | 1993-02-02 | The Scripps Research Institute | Ten-membered ring enediynediols and enediynediones having DNA cleaving properties |
US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5294770A (en) | 1992-01-14 | 1994-03-15 | Alza Corporation | Laser tablet treatment system with dual access to tablet |
US5688518A (en) | 1992-02-27 | 1997-11-18 | Alza Corporation | Antidepressive therapy |
US5185158A (en) | 1992-02-27 | 1993-02-09 | Alza Corporation | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same |
US5246710A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
US5246711A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
PT621032E (pt) | 1993-04-23 | 2001-01-31 | Novartis Ag | Dispositivo de distribuicao de libertacao controlada de farmaco |
US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
RO114740B1 (ro) | 1994-05-06 | 1999-07-30 | Pfizer | Compozitie cu eliberare controlata, procedeu de obtinere a acesteia si metoda de tratament |
US5698224A (en) | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5718700A (en) | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
US5658474A (en) | 1994-12-16 | 1997-08-19 | Alza Corporation | Method and apparatus for forming dispenser delivery ports |
US5607696A (en) | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
ZA97976B (en) * | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
ES2203963T3 (es) | 1997-05-30 | 2004-04-16 | Osmotica Corp. | Dispositivo osmotico multicapa. |
SK180499A3 (en) * | 1997-07-01 | 2001-08-06 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
-
2000
- 2000-12-13 JP JP2001548093A patent/JP2003518487A/ja not_active Withdrawn
- 2000-12-13 CA CA002395231A patent/CA2395231C/en not_active Expired - Fee Related
- 2000-12-13 BR BR0016707-0A patent/BR0016707A/pt not_active IP Right Cessation
- 2000-12-13 AU AU17243/01A patent/AU1724301A/en not_active Abandoned
- 2000-12-13 WO PCT/IB2000/001871 patent/WO2001047498A2/en not_active Application Discontinuation
- 2000-12-13 EP EP00979866A patent/EP1239839A2/en not_active Withdrawn
- 2000-12-13 MX MXPA02006335A patent/MXPA02006335A/es active IP Right Grant
- 2000-12-20 UY UY26493A patent/UY26493A1/es not_active Application Discontinuation
- 2000-12-20 US US09/745,096 patent/US6899896B2/en not_active Expired - Fee Related
- 2000-12-21 PE PE2000001381A patent/PE20010983A1/es not_active Application Discontinuation
- 2000-12-21 GT GT200000220A patent/GT200000220A/es unknown
- 2000-12-21 AR ARP000106853A patent/AR027066A1/es unknown
- 2000-12-21 CO CO00097187A patent/CO5271728A1/es not_active Application Discontinuation
- 2000-12-22 TN TNTNSN00251A patent/TNSN00251A1/fr unknown
- 2000-12-22 PA PA20008508901A patent/PA8508901A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003518487A (ja) | 2003-06-10 |
BR0016707A (pt) | 2002-09-03 |
EP1239839A2 (en) | 2002-09-18 |
CO5271728A1 (es) | 2003-04-30 |
AR027066A1 (es) | 2003-03-12 |
WO2001047498A3 (en) | 2001-11-15 |
US6899896B2 (en) | 2005-05-31 |
CA2395231C (en) | 2006-08-15 |
UY26493A1 (es) | 2001-07-31 |
MXPA02006335A (es) | 2002-12-13 |
CA2395231A1 (en) | 2001-07-05 |
GT200000220A (es) | 2002-06-14 |
US20010044474A1 (en) | 2001-11-22 |
PA8508901A1 (es) | 2003-12-10 |
TNSN00251A1 (fr) | 2002-05-30 |
AU1724301A (en) | 2001-07-09 |
WO2001047498A2 (en) | 2001-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010983A1 (es) | Forma de dosificacion de farmaco en capas impulsada por hidrogel | |
AR059324A2 (es) | Una forma solida de dosificacion oral | |
AR065827A2 (es) | Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina, composicion farmaceutica, procedimiento y preparacion y su uso en terapia | |
ES2545395T3 (es) | Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea | |
Serebro et al. | Inhibition of cholera toxin action in the rabbit by cycloheximide | |
AR039491A1 (es) | Metodos y formas de dosificacion para la entrega controlada de oxicodona | |
ES2194732T3 (es) | Composiciones farmaceuticas orales de liberacion controlada de mesalazina. | |
AR054350A2 (es) | Preparado farmaceutico que contiene acidos difosfonicos para la palicacion por via oral | |
JP2005500309A5 (es) | ||
ES2161874T3 (es) | Composicion oftalmica con viscosidad reducida. | |
SV2002000586A (es) | Formula de dosificacion de la droga accionada por hidrogel ref. pc11095/700006/b | |
AR065072A2 (es) | Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo | |
ES2167546T3 (es) | Mejoras introducidas en composiciones organicas. | |
AR047815A2 (es) | Proceso para producir una composicion farmaceutica en forma de dosificacion unitaria solida que contiene acido ibandronico | |
HU226588B1 (en) | Method for stabilizing pharmaceutical compositions by special use an antioxidant | |
ES2238941T1 (es) | Solvato de hemitartrato de zolpidem. | |
PE18898A1 (es) | Metodo para medicamentar el sistema de control inflamatorio y reacciones inflamatorias adversas y para fabricar compuestos para el tratamiento de la patologia de reacciones inflamatorias adversas | |
JP2013523676A5 (es) | ||
KR900000076A (ko) | 딜티아젬(diltiazem) 공급용의 제형(dosage form) | |
ES2553107T3 (es) | Composición anti-inflamatoria basada en compuestos de estroncio | |
JP2007510690A5 (es) | ||
ES2142430T3 (es) | Compuestos farmaceuticos en forma de gel conteniendo sales de sulfato de condroitina apropiadas para administracion oral. | |
ES2460967T3 (es) | Método para la prevención de la degradación de una sustancia térmicamente inestable | |
ES2399569T3 (es) | Composición farmacéutica líquida estable a base de trazodona | |
CO5550418A2 (es) | Formulaciones antihistaminicas para formas de dosificacion de capsula blanda |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |